ClinicalTrials.gg
CompletedNCT00111813Updated May 21, 2015Results posted

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

A Phase 1 interventional study of vorinostat and bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.

Enrollment
5th of 17
34 · median 31
Started
2005
with 1 other
Phase 1
10 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
6 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 1, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing vorinostat in Multiple Myeloma as a file.
02

Study summary

The purposes of this study are:

  • To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma
  • To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for this combination, as determined per standard of care.
03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with or relapsed multiple myeloma
  • (ECOG) performance status of 0-2 (a measurement to determine participant's ability to perform daily activities)
  • Adequate bone marrow reserve
  • Adequate hepatic and renal function
  • Ability to swallow capsules
  • 3 weeks or more since prior chemotherapy and have recovered from prior toxicities

Exclusion criteria

Exclusion Criteria:

  • Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment
  • Participants with prior treatment with other agents with a similar anti-tumor mechanism
  • Participants with other active/uncontrolled illness
  • Pregnant or nursing female participants
  • Participants who received bortezomib within 3 months of start of this trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    vorinostat 200 mg + bortezomib 0.7 mg/m^2

    Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.

    Drug: vorinostat · Drug: bortezomib

  • Experimental
    vorinostat 200 mg + bortezomib 0.9 mg/m^2

    Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.

    Drug: vorinostat · Drug: bortezomib

  • Experimental
    vorinostat 300 mg + bortezomib 1.3 mg/m^2

    Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.

    Drug: vorinostat · Drug: bortezomib

  • Experimental
    vorinostat 400 mg + bortezomib 0.9 mg/m^2

    Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.

    Drug: vorinostat · Drug: bortezomib

  • Experimental
    vorinostat 400 mg + bortezomib 1.1 mg/m^2

    Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.

    Drug: vorinostat · Drug: bortezomib

  • Experimental
    vorinostat 400 mg + bortezomib 1.3 mg/m^2

    Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.

    Drug: vorinostat · Drug: bortezomib

Interventions

  • Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

    Also known as: MK0683, Zolinza®, Suberoylanilide Hydroxamic Acid (SAHA)

  • Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

    Also known as: Velcade

06

What researchers measure

Primary outcomes

  1. Mean Duration of Treatment With Vorinostat

    Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity. Progressive disease was defined as: * \>25% increase in the level of serum monoclonal paraprotein. * 25% increase in 24-hour urinary light chain excretion. * \>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy. * Development of new bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia. Intolerable toxicity was based on the clinical judgment of the investigator.

    Time frame: Day 1 to an event causing discontinuation from the study, assessed up to 29 months

Secondary outcomes

  1. Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug

    An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.

    Time frame: Day 1 to disease progression, toxicity, or death, assessed up to 29 months

  2. Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.

    Time frame: Day 1 to disease progression, toxicity, or death, assessed up to 29 months

  3. Clinical AE Summary

    An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A serious AE (SAE) was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose.

    Time frame: Day 1 up to disease progression, toxicity, or death, assessed up to 30 days after end of treatment (up to 30 months)

  4. Laboratory AE Summary

    An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. A lab (S)AE was any lab value considered clinically significant in the investigator's judgment.

    Time frame: Day 1 up to disease progression, toxicity, or death, assessed up to 29 months

07

Results

Posted Apr 6, 2011

Participant flow

Participant flow — Overall Study
MilestoneVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
Started3310666
Completed000100
Not completed3310566
Withdrew: Adverse event124222
Withdrew: Progressive disease215343
Withdrew: Lack of efficacy000001
Withdrew: Other001000

Outcome measures

PrimaryMean Duration of Treatment With Vorinostat

Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity. Progressive disease was defined as: * \>25% increase in the level of serum monoclonal paraprotein. * 25% increase in 24-hour urinary light chain excretion. * \>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy. * Development of new bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia. Intolerable toxicity was based on the clinical judgment of the investigator.

Time frame:
Day 1 to an event causing discontinuation from the study, assessed up to 29 months
Reported as:
Mean · Days
Mean Duration of Treatment With Vorinostat
DaysAll Participants
200 mg4.6 (1 to 15)
300 mg72.6 (28 to 210)
400 mg107.1 (11 to 496)
SecondaryNumber of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug

An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.

Time frame:
Day 1 to disease progression, toxicity, or death, assessed up to 29 months
Reported as:
Number · Participants
Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug
ParticipantsVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
No dose modification338433
One dose modification002210
Two or more dose modifications000023
SecondaryMean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.

Time frame:
Day 1 to disease progression, toxicity, or death, assessed up to 29 months
Reported as:
Mean · Days
Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib
DaysVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or BortezomibNA ± NANA ± NA58 ± 3958 ± 11128 ± 14832 ± 5
SecondaryClinical AE Summary

An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A serious AE (SAE) was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose.

Time frame:
Day 1 up to disease progression, toxicity, or death, assessed up to 30 days after end of treatment (up to 30 months)
Reported as:
Number · Participants
Clinical AE Summary
ParticipantsVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
With one or more AEs3310666
With no AEs000000
With drug-related AEs2310666
With Serious AEs (SAEs)012442
With drug-related SAEs001421
Who died000000
Who discontinued due to AEs124212
Who discontinued due to drug-related AEs023211
Who discontinued due to SAEs001201
Who discontinued due to drug-related SAEs001200
SecondaryLaboratory AE Summary

An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. A lab (S)AE was any lab value considered clinically significant in the investigator's judgment.

Time frame:
Day 1 up to disease progression, toxicity, or death, assessed up to 29 months
Reported as:
Number · Participants
Laboratory AE Summary
ParticipantsVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
With one or more laboratory AEs113023
With no laboratory AEs227643
With drug-related laboratory AEs102013
With laboratory Serious AEs (SAEs)000000
With drug-related laboratory SAEs000000
Who died000000
Who discontinued due to laboratory AEs000000
Who discontinued due to drug-related lab AEs000000
Who discontinued due to laboratory SAEs000000
Who discontinued due to drug-related lab SAEs000000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat 200 mg + Bortezomib 0.7 mg/m^2—0/3 (0%)3/3 (100%)
Vorinostat 200 mg + Bortezomib 0.9 mg/m^2—1/3 (33.3%)3/3 (100%)
Vorinostat 300 mg + Bortezomib 1.3 mg/m^2—2/10 (20%)10/10 (100%)
Vorinostat 400 mg + Bortezomib 0.9 mg/m^2—4/6 (66.7%)6/6 (100%)
Vorinostat 400 mg + Bortezomib 1.1 mg/m^2—4/6 (66.7%)6/6 (100%)
Vorinostat 400 mg + Bortezomib 1.3 mg/m^2—2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
ThrombocytopeniaBlood and lymphatic system disorders0/30/30/100/62/60/6
PneumoniaInfections and infestations0/31/31/100/60/61/6
NeutropeniaBlood and lymphatic system disorders0/30/30/100/60/61/6
NauseaGastrointestinal disorders0/30/31/101/60/60/6
VomitingGastrointestinal disorders0/30/30/101/60/60/6
Chest painGeneral disorders0/30/30/101/60/60/6
DiverticulitisInfections and infestations0/30/30/101/60/60/6
HypermagnesaemiaMetabolism and nutrition disorders0/30/30/100/60/61/6
ArthralgiaMusculoskeletal and connective tissue disorders0/30/30/101/60/60/6
Pain in extremityMusculoskeletal and connective tissue disorders0/30/30/101/60/60/6
Most frequent other events
Showing 10 of 159
Most frequent other events
EventVorinostat 200 mg + Bortezomib 0.7 mg/m^2Vorinostat 200 mg + Bortezomib 0.9 mg/m^2Vorinostat 300 mg + Bortezomib 1.3 mg/m^2Vorinostat 400 mg + Bortezomib 0.9 mg/m^2Vorinostat 400 mg + Bortezomib 1.1 mg/m^2Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
ThrombocytopeniaBlood and lymphatic system disorders0/33/35/102/65/64/6
DiarrhoeaGastrointestinal disorders0/31/38/104/66/66/6
NauseaGastrointestinal disorders2/33/36/105/63/66/6
FatigueGeneral disorders2/33/35/106/62/65/6
VomitingGastrointestinal disorders1/32/36/103/63/65/6
Abdominal distensionGastrointestinal disorders2/31/30/100/60/60/6
ConstipationGastrointestinal disorders0/30/30/102/64/63/6
Weight decreasedInvestigations1/32/30/100/61/61/6
Decreased appetiteMetabolism and nutrition disorders0/31/31/100/62/64/6
DehydrationMetabolism and nutrition disorders0/32/31/101/60/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean60.6 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female13
Male21
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24. doi: 10.1016/j.clml.2012.07.007. PubMed 23040438 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Dec 2009 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2005
First posted
May 26, 2005
Start
Sep 2005
Primary completionActual
Dec 2009
CompletionActual
May 2011
Results first posted
Apr 6, 2011
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00111813
Responsible party
Sponsor
First posted
May 26, 2005
Start date
Sep 2005
Primary completion
Dec 2009
Completion
May 2011
Results posted
Apr 6, 2011
Last update
May 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion